Eligard: leuprolide acetate in a novel sustained-release delivery system
- 1 February 2003
- Vol. 61 (2) , 25-31
- https://doi.org/10.1016/s0090-4295(02)02396-8
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A Clinical Study Of 22.5 mg. La-2550: A New Subcutaneous Depot Delivery System For Leuprolide Acetate For The Treatment Of Prostate CancerJournal of Urology, 2002
- Reassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology, 2000
- Peptide analogs in the therapy of prostate cancerThe Prostate, 2000
- FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHMJournal of Urology, 2000
- Delivery of Proteins from a Controlled Release Injectable ImplantPublished by Springer Nature ,1996
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.Proceedings of the National Academy of Sciences, 1982